INNOVENT BIO - EFFECTIVENESS OF THE STRATEGIC COLLABORATION WITH LILLY

AND CLARIFICATION

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

EFFECTIVENESS OF THE STRATEGIC COLLABORATION WITH LILLY AND

CLARIFICATION

This announcement is made by Innovent Biologics, Inc. (the "Company" or "Innovent", together with its subsidiaries, the "Group") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

Reference is made to the announcement of the Company dated February 8, 2026 in relation to the signing of a strategic collaboration agreement with Lilly to advance novel medicines in oncology and immunology (the "Announcement"). Terms used in this announcement shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

The Board hereby announces that the Company has obtained early clearance from the Federal Trade Commission, and hence, all the conditions precedent to the effectiveness of the strategic collaboration agreement between Lilly and the Company had been satisfied. The strategic collaboration agreement became effective on March 24, 2026, Hong Kong time.

The Company notes that certain media reports have incorrectly interpretated the effectiveness of the strategic collaboration agreement as an acquisition of the Company. The Company clarifies that it is not engaged in, nor has any intention of pursuing such transaction. Shareholders and potential investors are advised not to rely on market rumours in relation to the Group. Any information concerning the Group should only be based on the Company's official announcement.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board

Innovent Biologics, Inc. Dr. De-Chao Michael Yu

Chairman and Executive Director

Hong Kong, China,

March 25, 2026